Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (RIG2) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (RIG2) has a cash flow conversion efficiency ratio of 0.040x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€52.44 Billion ≈ $61.30 Billion USD) by net assets (€1.30 Trillion ≈ $1.52 Trillion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see RIG2 company net worth for the company's overall valuation and market capitalisation.
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt ranked by their cash flow conversion efficiency. Explore Richter Gedeon Vegyészeti Gyár Nyilvános cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SICC Co. Ltd.
SHG:688234
|
-0.030x |
|
Huaibei Mining Holdings Co Ltd
SHG:600985
|
0.038x |
|
Baiyin Nonferrous Group Co Ltd
SHG:601212
|
0.041x |
|
PSP Swiss Property AG
SW:PSPN
|
0.007x |
|
Metallurgical Corporation of China Ltd
SHG:601618
|
0.019x |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607
|
0.017x |
|
SBI Cards and Payment Services Limited
NSE:SBICARD
|
0.007x |
|
Informatica Inc
NYSE:INFA
|
0.061x |
Annual Cash Flow Conversion Efficiency for Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (2013–2025)
The table below shows the annual cash flow conversion efficiency of Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt from 2013 to 2025. View Richter Gedeon Vegyészeti Gyár Nyilvános stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.40 Trillion ≈ $1.64 Trillion |
€276.40 Billion ≈ $323.14 Billion |
0.197x | -7.91% |
| 2024-12-31 | €1.30 Trillion ≈ $1.52 Trillion |
€279.37 Billion ≈ $326.61 Billion |
0.214x | +67.87% |
| 2023-12-31 | €1.14 Trillion ≈ $1.34 Trillion |
€145.84 Billion ≈ $170.50 Billion |
0.128x | -26.81% |
| 2022-12-31 | €1.06 Trillion ≈ $1.24 Trillion |
€184.93 Billion ≈ $216.20 Billion |
0.174x | +15.06% |
| 2021-12-31 | €923.02 Billion ≈ $1.08 Trillion |
€139.90 Billion ≈ $163.56 Billion |
0.152x | -7.60% |
| 2020-12-31 | €813.94 Billion ≈ $951.58 Billion |
€133.52 Billion ≈ $156.10 Billion |
0.164x | +21.07% |
| 2019-12-31 | €724.87 Billion ≈ $847.45 Billion |
€98.21 Billion ≈ $114.82 Billion |
0.135x | -7.41% |
| 2018-12-31 | €685.75 Billion ≈ $801.71 Billion |
€100.34 Billion ≈ $117.31 Billion |
0.146x | +16.02% |
| 2017-12-31 | €664.02 Billion ≈ $776.31 Billion |
€83.75 Billion ≈ $97.91 Billion |
0.126x | +11.08% |
| 2016-12-31 | €681.87 Billion ≈ $797.18 Billion |
€77.42 Billion ≈ $90.51 Billion |
0.114x | -26.13% |
| 2015-12-31 | €618.39 Billion ≈ $722.96 Billion |
€95.05 Billion ≈ $111.12 Billion |
0.154x | +38.81% |
| 2014-12-31 | €561.73 Billion ≈ $656.72 Billion |
€62.20 Billion ≈ $72.72 Billion |
0.111x | -17.46% |
| 2013-12-31 | €551.20 Billion ≈ $644.41 Billion |
€73.94 Billion ≈ $86.45 Billion |
0.134x | -- |
About Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. It offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women's lives. It also provides central nervous system products, such as products for the treatment of chron… Read more